The company’s AI approach allows molecule candidates to be vetted for efficacy and other properties early in development.

Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same ...

Bristol Myers (BMY) delivered an impressive performance in the past month after being under pressure for quite some time. The stock regained some of its lost ground and added 6.3% in a month compared ...

To get a sense of who is truly in control of Bristol-Myers Squibb Company (NYSE:BMY), it is important to understand the ...

Bristol Myers Squibb said on Friday its blockbuster drug Reblozyl in combination with another therapy failed to meet the main ...

Bristol Myers Squibb is making progress paying down debt from prior deals and improving financial flexibility so it can make ...

The Subject Expert Committee (SEC) under the Cardiovascular division of the Central Drugs Standard Control Organisation (CDSCO) has approved the protocol amendment submitted ...

Bristol-Myers Squibb Company (NYSE:BMY) is one of the largest and most well-known American pharmaceutical companies.

The program is the latest example of pharmaceutical companies bypassing traditional drug distribution channels for people who ...

Pharmaceutical giants introduce an insurance-free pathway for top anticoagulant Eliquis, following similar direct-to-patient ...

This was the stock's second consecutive day of losses.

The joint venture is launching a direct-to-consumer service of Eliquis after discussions with the Trump administration.